Drug intelligence / Profile preview

carboplatin + docetaxel + lenalidomide

Development stage: Unknown
Lead developer: Johnson Matthey
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination chemotherapy regimen consisting of carboplatin (a platinum-based alkylating agent), docetaxel (a taxane), and lenalidomide (an immunomodulatory drug). This combination has been studied in Phase I trials for advanced solid tumors, particularly non-small cell lung cancer, showing promising activity with manageable toxicity profiles.

Targets

CRBN (Cereblon)DNA

Beyond the preview

Go deeper on carboplatin + docetaxel + lenalidomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on carboplatin + docetaxel + lenalidomide.

Explore the full profile